These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18316628)

  • 21. Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.
    Sun JY; Tseng H; Xu L; Hunter Z; Ciccarelli B; Fulciniti M; Zhu B; Maghsoudi K; Yang G; Gong P; Zhou Y; Liu X; Munshi NC; Patterson CJ; Treon SP
    Leuk Lymphoma; 2011 Sep; 52(9):1777-86. PubMed ID: 21657958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
    Paulus A; Akhtar S; Caulfield TR; Samuel K; Yousaf H; Bashir Y; Paulus SM; Tran D; Hudec R; Cogen D; Jiang J; Edenfield B; Novak A; Ansell SM; Witzig T; Martin P; Coleman M; Roy V; Ailawadhi S; Chitta K; Linder S; Chanan-Khan A
    Blood Cancer J; 2016 Nov; 6(11):e492. PubMed ID: 27813535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
    Chauhan D; Singh AV; Ciccarelli B; Richardson PG; Palladino MA; Anderson KC
    Blood; 2010 Jan; 115(4):834-45. PubMed ID: 19965674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
    Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel treatment options for Waldenström macroglobulinemia.
    Leblebjian H; Agarwal A; Ghobrial I
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S310-6. PubMed ID: 24290218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia.
    Sacco A; Ghobrial IM; Roccaro AM
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1025-9. PubMed ID: 21933107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
    Dimopoulos MA; Terpos E; Kastritis E
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):235-7. PubMed ID: 23562304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Waldenström's macroglobulinemia].
    Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
    Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics-Pharmacodynamics Modeling and Evaluation of Tumor Response to Bortezomib Proteasome Inhibitor in Waldenstrom Macroglobulinemia.
    Munir A; Fazal S; Bhatti AI; Sajjad B
    Am J Clin Oncol; 2023 Apr; 46(4):150-160. PubMed ID: 36808095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
    Moreau AS; Jia X; Patterson CJ; Roccaro AM; Xu L; Sacco A; O'Connor K; Soumerai J; Ngo HT; Hatjiharissi E; Hunter ZR; Ciccarelli B; Manning R; Ghobrial IM; Leleu X; Treon SP
    Br J Haematol; 2008 Sep; 142(5):775-85. PubMed ID: 18537966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia.
    Madamsetty VS; Paulus A; Akhtar S; Manna A; Rachamalla HR; Banerjee R; Mukhopadhyay D; Chanan-Khan A
    Leuk Lymphoma; 2020 Oct; 61(10):2399-2408. PubMed ID: 32558607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
    Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
    Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.